It appears as though Bill Freytag, Ph.D. former chief executive of Myogen will be assuming the CEO and chair positions with Aspreva Pharmaceuticals (NASDAQ: ASPV) effective immediately. We wish him the best of luck in this next chapter and appreciate all that Dr. Freytag has done for the Colorado life science landscape. Aspreva, based in Victoria, British Columbia has two Phase III trials underway for the autoimmune diseases lupus nephritis and pemphigus vulgaris.
More news to come…
Wednesday, July 11, 2007
J. William Freytag: CEO of Aspreva Pharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment